Understanding the role of a specific gene in corneal health and disease
Investigating the Action and Physiological Role of Slc4a11 in the Cornea
This study is looking at how changes in a specific gene can affect eye cells that help keep your vision clear, and it's designed for older adults who might be at risk for a condition called Fuchs Endothelial Corneal Dystrophy, with hopes of finding new ways to help prevent or slow down vision loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10918260 on NIH RePORTER |
What this research studies
This research investigates how mutations in the SLC4A11 gene affect corneal endothelial cells, which are crucial for maintaining clear vision. By using a specially developed mouse model that mimics a human genetic mutation linked to Fuchs Endothelial Corneal Dystrophy (FECD), the study aims to uncover the molecular mechanisms that lead to this condition. The researchers will explore how these mutations impact cell function and contribute to vision loss, with the goal of developing non-invasive therapies to prevent or delay the onset of FECD in older adults.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Fuchs Endothelial Corneal Dystrophy, particularly those with a family history of the condition.
Not a fit: Patients with corneal diseases unrelated to SLC4A11 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent vision loss in patients with Fuchs Endothelial Corneal Dystrophy.
How similar studies have performed: While the approach of using genetic models to study corneal diseases is established, the specific focus on SLC4A11 and its role in FECD is relatively novel.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Parker, Mark — State University of New York at Buffalo
- Study coordinator: Parker, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.